World Health Organization Raises Warning Over Severe Shortage of Weight-Loss Jabs
Under 10% of people who could benefit from obesity jabs such as Wegovy can access them, caution the WHO as it publishes its first guidance on the therapies.
Given in excess of 1,000,000,000 individuals worldwide now living with obesity, it is calling for broader and more equitable access to these injectable treatments.
Per forecasts, more than two billion are projected to be living with obesity by 2030 unless action is taken.
"Our latest guidelines acknowledges that obesity is a chronic disease that can be addressed with thorough and ongoing care," remarked its chief Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and supply-chain constraints are key barriers to widespread access to the injections that can assist patients in reducing substantial body mass, explains the organization.
Skinny Jab Supply Crisis
Even under the present best projected scenario, the production of such drugs would only suffice for approximately 100 million people – less than 10% of those who need them, as stated by the WHO.
The recommendation calls on nations and manufacturers to expand access, by measures including licensing agreements.
Exclusive production rights on the active ingredient – the core component of Novo Nordisk's Wegovy – is scheduled to end in a number of countries in 2026.
The Way Obesity Drugs Operate
These medications imitate a natural hormone to slow digestion, reduce hunger and increase satiety so individuals consume fewer calories.
Individuals typically see weight reduction after several weeks of starting on the regular doses.
Studies indicates users may put most of the weight back on a year later of discontinuing the treatment, when their typical appetite return.
To be above a healthy weight increases your risk for developing diseases, like diabetes, cardiovascular issues, stroke, and some cancers.
Obesity concerns individuals in all nations and was linked to millions of deaths worldwide in 2024, per the WHO.
